IDEXX Laboratories (IDXX) Receiving Somewhat Favorable Media Coverage, Report Finds

Media headlines about IDEXX Laboratories (NASDAQ:IDXX) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. IDEXX Laboratories earned a news impact score of 0.03 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.7121694398402 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Shares of IDEXX Laboratories (IDXX) traded up $6.99 during midday trading on Monday, hitting $197.30. 563,332 shares of the stock were exchanged, compared to its average volume of 583,056. The firm has a market cap of $16,580.34, a P/E ratio of 67.11, a P/E/G ratio of 2.33 and a beta of 0.58. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. IDEXX Laboratories has a fifty-two week low of $146.09 and a fifty-two week high of $207.14.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business’s revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.58 EPS. equities research analysts forecast that IDEXX Laboratories will post 4.11 earnings per share for the current fiscal year.

A number of analysts have commented on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a report on Monday, January 29th. BidaskClub upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective for the company in a report on Monday, February 5th. Piper Jaffray increased their price objective on shares of IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, Aegis reiterated a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $194.00.

In other news, VP Brian P. Mckeon sold 6,602 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the completion of the sale, the vice president now owns 47,040 shares in the company, valued at approximately $8,531,174.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William T. End sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $184.48, for a total transaction of $737,920.00. Following the sale, the director now owns 41,256 shares of the company’s stock, valued at approximately $7,610,906.88. The disclosure for this sale can be found here. Insiders have sold a total of 91,736 shares of company stock valued at $16,193,502 in the last 90 days. Insiders own 2.77% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3303171/idexx-laboratories-idxx-receiving-somewhat-favorable-media-coverage-report-finds.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Whiting Petroleum  Sets New 52-Week High and Low at $40.47
Whiting Petroleum Sets New 52-Week High and Low at $40.47
SilverBow Resources  Reaches New 52-Week High and Low at $34.76
SilverBow Resources Reaches New 52-Week High and Low at $34.76
Financial Comparison: Service Co. International  versus Yelp
Financial Comparison: Service Co. International versus Yelp
Critical Contrast: Morgan Stanley  and Its Competitors
Critical Contrast: Morgan Stanley and Its Competitors
Barfresh Food Group  vs. Lamb Weston  Head to Head Survey
Barfresh Food Group vs. Lamb Weston Head to Head Survey
Royal Bank of Canada Increases American Express  Price Target to $86.00
Royal Bank of Canada Increases American Express Price Target to $86.00


© 2006-2018 Ticker Report. Google+.